Innovent Biologics, Inc.

OTCPK:IVBX.F Stock Report

Market Cap: US$7.4b

Innovent Biologics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:IVBX.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Dec 24SellUS$3,874,405JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany803,621US$4.82
30 Oct 24SellUS$39,665,163JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany8,668,935US$4.58
29 Oct 24BuyUS$22,367,077JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany4,592,813US$4.87
10 Oct 24SellUS$68,722,897JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany10,891,140US$6.31
08 Oct 24BuyUS$70,495,950JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany11,412,177US$6.18
02 Oct 24SellUS$10,454,736De-Chao YuIndividual1,750,000US$6.02
30 Sep 24SellUS$9,084,814De-Chao YuIndividual1,500,000US$6.10
27 Sep 24SellUS$4,330,187Hao Xi EdeIndividual736,500US$5.88
26 Sep 24SellUS$469,386Hao Xi EdeIndividual81,500US$5.76
11 Sep 24BuyUS$11,040JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany2,000US$5.52
11 Sep 24BuyUS$11,040JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany2,000US$5.52
11 Sep 24SellUS$223,559JP Morgan Asset ManagementCompany40,500US$5.52
11 Sep 24SellUS$85,461,245JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany15,482,177US$5.52
10 Sep 24BuyUS$57,544,602JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany10,624,087US$5.42
10 Jul 24SellUS$12,728,577Capital Research and Management CompanyCompany2,755,000US$4.62
03 May 24SellUS$4,683,731De-Chao YuIndividual906,250US$5.17
02 Feb 24BuyUS$7,773,313Capital Research and Management CompanyCompany1,869,776US$4.16
12 Jan 24BuyUS$6,636,262Capital Research and Management CompanyCompany1,292,500US$5.13
05 Jan 24SellUS$17,121,093Capital Research and Management CompanyCompany3,456,000US$4.95

Insider Trading Volume

Insider Buying: IVBX.F insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IVBX.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies10,614,5000.648%
VC/PE Firms89,475,3505.46%
Individual Insiders110,666,8236.76%
Institutions687,529,02042%
General Public739,624,15345.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 45.28% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.92%
Capital Research and Management Company
113,425,003US$513.5m-0.65%0.02%
6.53%
De-Chao Yu
107,003,778US$484.4m-1.61%no data
5.46%
SDIC Innovation Investment Management Co., Ltd.
89,475,350US$405.1m0%25.15%
3.58%
The Vanguard Group, Inc.
58,590,227US$265.2m0.48%no data
2.74%
BlackRock, Inc.
44,918,246US$203.3m5.6%no data
2.22%
GF Fund Management Co., Ltd.
36,440,000US$165.0m0%0.34%
2.03%
Fidelity International Ltd
33,326,440US$150.9m-1.1%0.06%
1.98%
Norges Bank Investment Management
32,441,094US$146.9m0%0.01%
1.82%
Temasek Holdings (Private) Limited
29,751,000US$134.7m136%0.12%
1.52%
Citigroup Inc.,Banking and Securities Investments
24,932,063US$112.9m0%0.08%
1.46%
Bosera Asset Management Co., Ltd.
23,965,000US$108.5m0%0.48%
1.43%
Harvest Fund Management Co. Ltd.
23,397,288US$105.9m0%0.23%
1.14%
E Fund Management Co., Ltd.
18,603,000US$84.2m0%0.1%
0.82%
FMR LLC
13,398,681US$60.7m0%no data
0.76%
Schroder Investment Management Limited
12,410,500US$56.2m1.4%0.04%
0.73%
China Asset Management Co. Ltd.
11,944,751US$54.1m-0.96%0.06%
0.6%
Polar Capital Holdings Plc
9,834,562US$44.5m2.73%0.16%
0.59%
Schroder Investment Management North America Inc.
9,651,500US$43.7m-0.01%0.14%
0.51%
ICBC Credit Suisse Asset Management Co., Ltd.
8,343,974US$37.8m0%0.2%
0.48%
Invesco Ltd.
7,802,000US$35.3m1.36%0.01%
0.45%
Schroder Investment Management (Hong Kong) Ltd.
7,410,000US$33.5m0%0.2%
0.41%
Fullerton (Private) Limited
6,673,500US$30.2m0%no data
0.39%
Bank of China Investment Management Co., Ltd.
6,356,000US$28.8m0%0.65%
0.36%
UBS Asset Management AG
5,833,209US$26.4m28.7%no data
0.35%
Geode Capital Management, LLC
5,729,863US$25.9m1.88%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innovent Biologics, Inc. is covered by 53 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Bo LiBofA Global Research